Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

• US 6,277,855 B1
• Filed: 04/21/2000
• Issued: 08/21/2001
• Est. Priority Date: 04/21/2000
• Status: Expired due to Fees

• Current Assignee: Inspire Pharmaceuticals Incorporated (Akorn Holdings Topco LLC)
• Original Assignee: Inspire Pharmaceuticals Incorporated (Akorn Holdings Topco LLC)
• Inventors: Yerxa, Benjamin R.
• Primary Examiner(s): FAY, ZOHREH A
• Application Number:
  US09/557,059
• Time in Patent Office: 487 Days
• Field of Search: 514/256, 514/299, 514/912
• US Class Current: 514/256
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a method for increasing hydration and lubrication of lacrimal tissues in a subject in need of such treatment. The method comprises administering to the subject a nicotinic acetylcholine receptor agonist such as nicotine and its analogs, transmetanicotine and its analogs, epibatidine and it analogs, lobeline and its analogs, pyridol derivatives, para-alkylthiophenol derivatives, and imidacloprid and its analogs, in an amount effective to stimulate mucus secretion in the lacrimal system. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the formulation include: topical administration via a liquid, gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liquid or pill), injectable, intra-operative instillation, suppository form, or transdermal form. The invention is useful for treating dry eye disease and corneal injury.

Claims

1. A method of treating dry eye disease comprising administering to a subject in need of such treatment a therapeutically effective amount of a nicotinic acetylcholine receptor agonist in a pharmaceutically effective carrier.

2. The method according to claim 1, wherein said nicotinic acetylcholine receptor agonist is selected from the group consisting of compounds of Formula I-X:

wherein;

n is an integer between 0-3;

n′

is an integer between 1-3;

R₁, and R₃ are H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl, C₄-C₇ cycloalkenyl, C₁-C₆ alkoxy, Cl, Br, I, or amino;

wherein at least one hydrogen of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, C₁-C₆ alkoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C_1-4 alkylamino, and di-C_1-4 alkylamino, wherein said alkyl groups are optionally linked to form a heterocycle; and

R₂ and R₄ are H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalky, C₄-C₇ cycloalkenyl, C₁-C₆ alkoxy, or amino;

wherein at least one hydrogen of said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, C₁-C₆ alkoxy, is optionally substituted with a moiety selected from the group consisting of halogen, hydroxy, carboxy, cyano, nitro, sulfonamido, sulfonate, phosphate, sulfonic acid, amino, C_1-4 alkylamino, and di-C_1-4 alkylamino, wherein said alkyl groups are optionally linked to form a heterocycle;

optionally R₂ and R₄ in Formula II are linked to form a 5 or 6-membered ring.

3. A method according to claim 2, wherein said nicotinic acetylcholine receptor agonist is nictotine and its analogs.

4. A method according to claim 2, wherein said nicotinic acetylcholine receptor agonist is trans-metanicotine and its analogs.

5. A method according to claim 2, wherein said nicotinic acetylcholine receptor agonist is a pyridol derivative.

6. A method according to claim 2, wherein said nicotinic acetylcholine receptor agonist is a piperidine alkaloid.

7. A method according to claim 2, wherein said nicotinic acetylcholine receptor agonist is a para-alkylthiophenol derivative.

8. The method according to claim 1, wherein said administering involves topical administration of said compound.

9. The method according to claim 8, wherein said topical administration is via a carrier vehicle selected from a group consisting of drops of liquid, liquid washes, gels, ointments, sprays and liposomes.

10. The method according to claim 8, wherein said topical administration comprises infusion of said compound to said ocular surface via a device selected from a group consisting of a pump-catheter system, a continuous or selective release device and a contact lens.

11. The method according to claim 1, wherein said administering is systemic administration of said compound.

12. The method according to claim 11, wherein said systemic administration involves administration of a liquid/liquid suspension of said compound via nose drops or nasal spray, or administration of a nebulized liquid to oral or nasopharyngeal airways of said subject, such that a therapeutically effective amount of said compound contacts lacrimal tissues of said subject via systemic absorption and circulation.

13. The method according to claim 11, wherein said systemic administration of said compound is accomplished by administering an oral form of said compound, such that a therapeutically effective amount of said compound contacts lacrimal tissues of said subject via systemic absorption and circulation.

14. The method according to claim 13, wherein said oral form is a chewable gum.

15. The method according to claim 11, wherein said systemic administration involves administration of an injectable form of said compound, such that a therapeutically effective amount of said compound contacts lacrimal tissues of said subject via systemic absorption and circulation.

16. The method according to claim 11, wherein said systemic administration involves administration of a suppository form of said compound, such that a therapeutically effective amount of said compound contacts lacrimal tissues of said subject via systemic absorption and circulation.

17. The method according to claim 11, wherein said systemic administration involves administration of an intra-operative instillation of a gel, cream, powder, foam, crystals, liposomes, spray or liquid suspension form of said compound, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

18. The method according to claim 11, wherein said systemic administration involves administration of said compound in a form of a transdermal patch or a transdermal pad, such that a therapeutically effective amount of said compound contacts the lacrimal tissues of said subject via systemic absorption and circulation.

21. A method of treating corneal injury comprising administering to a subject in need of such treatment a pharmaceutical formulation comprising a therapeutically effective amount of a nicotinic acetylcholine receptor agonist selected from the group consisting of compounds of Formulae I-X as described in claim 2.

19. A method of increasing hydration and lubrication of ocular surfaces comprising the steps of administering to a subject an amount of a nicotinic acetylcholine receptor agonist effective to stimulate conjunctival goblet cells to secrete mucins.

20. The method according to claim 19, wherein said nicotinic acetylcholine receptor agonist is selected from the group consisting of compounds of Formula I-X as described in claim 2.